Aclaris Therapeutics Inc (ACRS)

NASDAQ
18.16
+0.70(+4.01%)
After Hours
18.16
0.00(0.00%)
- Real-time Data
  • Volume:
    1,488,014
  • Bid/Ask:
    16.80/18.40
  • Day's Range:
    17.37 - 18.80
  • Type:Equity
  • Market:United States
  • ISIN:US00461U1051
  • CUSIP:00000461U105

ACRS Overview

Prev. Close
17.46
Day's Range
17.37-18.8
Revenue
6.63M
Open
17.55
52 wk Range
2.25-30.38
EPS
-1.47
Volume
1,488,014
Market Cap
1.11B
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
562,809
P/E Ratio
-
Beta
0.62
1-Year Change
617.79%
Shares Outstanding
61,215,707
Next Earnings Date
09 Nov 2021
What is your sentiment on Aclaris Therapeutics Inc?
or
Market is currently closed. Voting is open during market hours.

Aclaris Therapeutics Inc News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellNeutralBuyStrong BuyStrong Buy
Technical IndicatorsStrong SellSellStrong BuyStrong BuyStrong Buy
SummaryStrong SellNeutralStrong BuyStrong BuyStrong Buy

Aclaris Therapeutics Inc Company Profile

Aclaris Therapeutics Inc Company Profile

Employees
60

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing drug candidates for immuno-inflammatory diseases. Its drug candidates include ATI-450, ATI-1777, ATI-2138 and Undisclosed- Gut Restricted Program. Its ATI-450 is an investigational oral, small molecule selective mitogen-activated protein kinase-activated protein kinase 2, or MK2, inhibitor compound, for the treatment of rheumatoid arthritis. Its ATI-1777 is an investigational topical soft-JAK inhibitor compound, for the treatment of atopic dermatitis. Its ATI-2138 is an investigational oral ITK/TXK/JAK3, or ITJ, inhibitor compound, as al treatment for psoriasis and/or inflammatory bowel disease, which are both T-cell mediated autoimmune diseases.

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.